Tag: ChAdOx1 nCoV-19 vaccine

1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one month after vaccination. 2. Combined vaccine efficacy of the Pfizer and AstraZeneca in preventing hospital admission due to COVID-19 among those aged 80 years and older was approximately 83%. Evidence Rating...
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant.  2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection. Evidence Rating Level: 1 (Excellent)      Study Rundown: With the emergence of COVID-19 variants, there is the...
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant.  2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection. Evidence Rating Level: 1 (Excellent)      Study Rundown: With the emergence of COVID-19 variants, there...
1. ChAdOx1 nCov-19 vaccine has been linked to immune thrombotic thrombocytopenia in patients after vaccination resembling autoimmune heparin-induced thrombocytopenia. 2. Treatment options for this disorder include high-dose intravenous immune globulin and anticoagulants approved for the treatment of heparin-induced thrombocytopenia. Evidence Rating Level: 4 (Below Average)    Study Rundown: Vaccines are the first-line defense...
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The neutralizing titer of the vaccinated individuals was nine times lower against B.1.1.7 than the non-B.1.1.7 (Victoria) strain in vitro. Evidence Rating Level: 1 (Excellent) Study Rundown: As vaccines are distributed worldwide, concern...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there were no hospital admissions for COVID-19 in the ChAdOx1-nCoV-19 group.  Evidence Rating Level: 1 (Excellent) Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems across the globe...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there were no hospital admissions for COVID-19 in the ChAdOx1-nCoV-19 group.  Evidence Rating Level: 1 (Excellent) Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems...